FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200
Debt
Debt-to-Equity Ratio0.19
Current Ratio8.61
Quick Ratio8.61
Price-To-Earnings
Trailing P/E Ratio-36.94
Forward P/E Ratio-40.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$125.67 million
Price / Sales42.47
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book9.01
Profitability
EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-102.86%
Return on Equity-27.70%
Return on Assets-16.78%
Miscellaneous
Employees423
Outstanding Shares83,520,000
Market Cap$5,337.06
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.01. The biopharmaceutical company earned $31.90 million during the quarter, compared to analysts' expectations of $29.07 million. FibroGen had a negative net margin of 102.86% and a negative return on equity of 27.70%. The firm's revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.48) earnings per share. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
7 brokers have issued 1 year price targets for FibroGen's shares. Their predictions range from $31.00 to $88.00. On average, they expect FibroGen's share price to reach $68.8333 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View Analyst Ratings for FibroGen.
What is the consensus analysts' recommendation for FibroGen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about FibroGen stock?
Here are some recent quotes from research analysts about FibroGen stock:
- 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (7/10/2018)
- 2. Mizuho analysts commented, "We took a closer look at Fibrogen’s pipeline product Pamrevlumab, currently in development for the treatment of diseases associated with fibrosis. We are encouraged by recent positive data in two indications; idiopathic pulmonary fibrosis (IPF) and pancreatic cancer. We believe the data lends credibility to the compound’s mechanism of action and we also highlight superior data in IPF vs. standard of care products. We reiterate our Buy rating and raise our PT to $74." (6/19/2018)
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Beigene (BGNE), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX) and SAGE Therapeutics (SAGE).
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
- Mr. Pat Cotroneo, Chief Financial Officer (Age 54)
- Dr. K. Peony Yu, Chief Medical Officer (Age 56)
- Mr. Julian N. Stern, Sec. (Age 93)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Has FibroGen been receiving favorable news coverage?
News coverage about FGEN stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. FibroGen earned a news impact score of 0.04 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 48.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by a number of of retail and institutional investors. Top institutional investors include Handelsbanken Fonder AB (0.21%), Xact Kapitalforvaltning AB (0.01%) and Verde Servicos Internacionais S.A. (0.01%). Company insiders that own FibroGen stock include Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which major investors are selling FibroGen stock?
FGEN stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A.. Company insiders that have sold FibroGen company stock in the last year include James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr. View Insider Buying and Selling for FibroGen.
Which major investors are buying FibroGen stock?
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $63.90.
How big of a company is FibroGen?
FibroGen has a market capitalization of $5.34 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
